Posted by Michael Wonder on 21 Feb 2026
MHRA approves zanidatamab (Ziihera) for the treatment of biliary tract cancer
19 February 2026 - Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body.
The MHRA has today, 19 February 2026, approved zanidatamab (Ziihera) for use in adults to treat biliary tract cancer whose cancer has high levels of a protein called HER2 and has progressed after previous treatment.
